Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease

BACKGROUND: Finerenone (BAY 94-8862) is a potent non-steroidal, selective mineralocorticoid receptor antagonist being developed for the treatment of patients with type 2 diabetes and chronic kidney disease. METHODS: We present the population pharmacokinetics and pharmacodynamics (PD) analysis for ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Snelder, Nelleke, Heinig, Roland, Drenth, Henk-Jan, Joseph, Amer, Kolkhof, Peter, Lippert, Jörg, Garmann, Dirk, Ploeger, Bart, Eissing, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051931/
https://www.ncbi.nlm.nih.gov/pubmed/31583611
http://dx.doi.org/10.1007/s40262-019-00820-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051931/
https://www.ncbi.nlm.nih.gov/pubmed/31583611
http://dx.doi.org/10.1007/s40262-019-00820-x

Ejemplares similares